Clinical Trial Update: Impact of Perioperative Levosimendan on Patients Undergoing Cardiac Surgery With Low Ejection Fraction [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing perioperative levosimendan in patients undergoing cardiac surgery with low ejection fraction has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Heart Failure with Reduced Ejection Fraction

Drugs mentioned

• Levosimendan (levosimendan)

Snippet

Sponsor: Zagazig University | Conditions: Cardiac Surgery, Low Ejection Fraction | Phase 2 | Status: COMPLETED